Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
1999-08-30
2002-02-26
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
C530S350000
Reexamination Certificate
active
06350446
ABSTRACT:
FIELD OF INVENTION
This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the hyaluronan synthase family, hereinafter referred to as HOEFC11. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.
BACKGROUND OF THE INVENTION
Hyaluronic acid (HA), an important constituent of extracellular matrix, is a linear polysaccharide of alternating glucuronic acid and N-acetyl glucosamine residues. It is synthesized by a membrane-bound enzyme hyaluronan synthase (HAS) and extruded into the extracellular space. Cloning of two human HAS (HAS 1 and HAS 2) has been reported very recently (K. Watanabe and Y. Yamaguchi, J. Biol. Chem. 271:22945-22948, 1996) (N. Itano and K. Kimata, Biochem. Biophy. Res. Communications, 222:816-820, 1996). HA synthesis is involved in many cellular functions such as migration, invasion, adhesion, transformation, proliferation and wound healing. HA synthesis has been shown to be induced by FBS, PDGF, EGF, IL-1, retinoic acid, IGF, TGF beta, etc. Increased HA production is: (a) a general phenomenon in various organs attacked by inflammatory cells, (b) implicated in tissue edema, (c) a characteristic of tissue remodeling and (d) a marker for early stage of extracellular matrix remodeling following vascular injury. Increased levels of HA have been reported in chronic renal failure, inflammatory diseases, cancer (prostate, mammary and other invasive tumors), aortas from diabetic patients, smaller airways of patients with acute alveolitis, transplantation edema in rejecting heart and kidney, myocardial ischemia, balloon injury, liver cirrhosis, wound healing and angiogenesis. Hyaluronidase (breaks down HA) is reported to be beneficial in limiting cellular damage during myocardial ischemia in rat, dog and man. This indicates that the hyaluronan synthase family has a established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further members of the hyaluronan synthase family which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, chronic renal failure, inflammatory diseases, myocardial ischemia, cancer, rheumatoid arthritis, cirrhotic liver disease.
SUMMARY OF THE INVENTION
In one aspect, the invention relates to HOEFC11 polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such HOEFC11 polypeptides and polynucleotides. Such uses include the treatment of chronic renal failure, inflammatory diseases, myocardial ischemia, cancer, rheumatoid arthritis, cirrhotic liver disease, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with HOEFC11 imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate HOEFC11 activity or levels.
REFERENCES:
patent: 0 893 506 (1999-01-01), None
patent: WO 97/40174 (1997-10-01), None
patent: WO 98/00551 (1998-01-01), None
Haubeck et al (Arthritis & Rheumatism vol. 38(5) pp 669-677), May 1995.*
Watanabe et al., “Molecular Identification of a Putative Human Hyaluronan Synthase*”, The Journal of Biological Chemistry, vol. 271, No. 38, pp. 22945-22948, Sep. 1996.
Itano et al., “Molecular Cloning of Human Hyaluronan Synthase1”, Biochemical and Biophysical Research Communications, vol. 222, pp. 816-820, (1996).
Brecht et al., “Increased hyaluronate synthesis is required for fibroblast detachment and mitosis”, Biochem. J., vol. 239, pp. 445-450, (1986).
Matuoka et al., “Hyaluronate Synthetase Inhibition by Normal and Transformed Human Fibroblasts during during Growth Reduction”, The Journal of Cell Biology, vol. 104, pp. 1105-1115, Apr. 1987.
Kitchen et al., “Synthesis and release of hyaluronic acid by Swiss 3T3 fibroblasts”, Biochem J., vol. 309, pp. 649-656 (1995).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue” The Journal of Cell Biology, vol. 111, pp. 2129-2138 (1990).
Kumar et al., “Molecular Cloning of a Plasma Membrane Calcium Pump form Human Osteoblasts”, Journal of Bone and Mineral Research, vol. 8 (4) pp. 505-513 (1993).
Salgaller et al., “Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating Lymphocytes with MAGE-1 synthetic peptide”, Cancer Immunology Immunotherapy vol. 39 pp 105-116 1994.
Lazar et al., “Transforming Growth Factor &agr;: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities” Molecular and Cellular Biology, vol. 8(1) pp. 1247-1252 (1988).
Spicer, et al., “Characterization and Molecular Evolution of a Vertebrate Hyaluronan Synthase Gene Family”, The Journal of Biological Chemistry, vol. 273, pp. 1923-1932 (1998).
Nambi Ponnal
Pullen Mark A
Zhu Yuan
Hecht Elizabeth J.
King William T.
Navarro Mark
Ratner & Prestia
SmithKline Beecham Corporation
LandOfFree
HAS2 splicing variant HOEFC11: a target in chronic renal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HAS2 splicing variant HOEFC11: a target in chronic renal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HAS2 splicing variant HOEFC11: a target in chronic renal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2953702